| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gita Ramjee | Q42571276 |
| Kenneth Mayer | Q54230575 | ||
| P2860 | cites work | Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects | Q24610019 |
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| Preexposure prophylaxis for HIV prevention: where have we been and where are we going? | Q26825042 | ||
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial | Q28292876 | ||
| Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa | Q28533158 | ||
| Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco | Q28658226 | ||
| Preexposure prophylaxis for HIV infection among African women | Q29620077 | ||
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana | Q29620078 | ||
| Tenofovir-based preexposure prophylaxis for HIV infection among African women | Q30621914 | ||
| FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis | Q33762990 | ||
| Can we stop AIDS with antiretroviral-based treatment as prevention? | Q34210416 | ||
| Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? | Q34379806 | ||
| Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use | Q34448430 | ||
| Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation | Q34606560 | ||
| Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice | Q34680992 | ||
| Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? | Q34968312 | ||
| Microbicides for HIV prevention | Q35770899 | ||
| Risk compensation: the Achilles' heel of innovations in HIV prevention? | Q36417699 | ||
| Pre-exposure prophylaxis for HIV infection: what if it works? | Q36872933 | ||
| Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs | Q37003938 | ||
| Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies | Q38068661 | ||
| Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis | Q43201094 | ||
| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study | Q46333832 | ||
| Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a | Q55546871 | ||
| P433 | issue | 4 | |
| P921 | main subject | HIV | Q15787 |
| HIV transmission | Q49029021 | ||
| P304 | page(s) | 226-232 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Current Opinion in HIV and AIDS | Q15724409 |
| P1476 | title | The current status of the use of oral medication to prevent HIV transmission | |
| P478 | volume | 10 |
| Q38834636 | "Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation |
| Q36901505 | A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. |
| Q59360577 | Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C |
| Q49711583 | Context appropriate interventions to prevent syphilis: a narrative review. |
| Q52580522 | Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. |
| Q33718592 | Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015 |
| Q36995385 | Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support |
| Q57613821 | HIV and sexually transmitted infections: responding to the "newest normal" |
| Q38695854 | Health and budget impact of combined HIV prevention - first results of the BELHIVPREV model. |
| Q40764132 | NextGen HIV prevention: new possibilities and questions |
| Q55715002 | Pre-exposure Prophylaxis: The Delivery Challenge. |
| Q55346967 | Prevention paradox: Medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. |
| Q36053059 | Putting PrEP into Practice: Lessons Learned from Early-Adopting U.S. Providers' Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated Care |
| Q89763042 | The Ashodaya PrEP project: Lessons and implications for scaling up PrEP from a community-led demonstration project among female sex workers in Mysore, India |
| Q37019969 | The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships |
| Q37143376 | Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action |
Search more.